Soon, Americans may have another option for a vaccine against Covid that will hit the market, and this is a more conventional injection that people may be more familiar with.
The pharmaceutical giant Sanofi, based in Franceand GlaxoSmithKline (GSK), based in the United Kingdom, have submitted a joint application to the Food and Drug Administration (FDA) for authorization for two doses COVID-19 vaccine and booster.
The vaccine is a protein-based vaccine, making it similar to the flu vaccine and other vaccines Americans received in their youth, rather than the new mRNA vaccines developed by Pfizer and Moderna.
Clinical trials have also shown promise for stroke, showing nearly 60 percent effectiveness in preventing symptomatic Covid infection and 100 percent effectiveness against hospitalization or death caused by the virus.
Like Novavax – which is also seeking authorization for a protein-based vaccine from the FDA – GSK and Sanofi are arriving late in the market after facing problems in preparation for the application, but could be major players in future deployments. Covid’s annual amplifiers.
After delays due to human error at the start of the trials, GSK and Sanofi have finally applied for FDA approval for their protein-based vaccine against COVID-19. This is a two-dose injection and companies are also planning a booster (photo file)
The shot showed great effectiveness in clinical trials, showing 100% effectiveness in preventing hospitalization or death from the virus. The booster was also very effective, increasing the antibody levels of mRNA vaccine recipients by up to 30-fold
“The evolving epidemiology of COVID-19 demonstrates the need for different vaccines,” said Roger Connor, president of GSK.
“We are confident that this vaccine can play an important role as we continue to tackle this pandemic and prepare for the post-pandemic period.”
Differences between mRNA and protein vaccines
- mRNA vaccines became popular during the COVID-19 pandemic, when Pfizer-BioNTech and Moderna released two-dose vaccines
Vaccines supply the body with materials to create its own viral protein. The immune system then destroys this protein and makes viral antibodies
mRNA photos are easier to develop and cheaper to make, but more expensive to transport
- Protein vaccines are the standard in America, and the 16 vaccines scheduled in the United States for humans before the age of 18 are all protein vaccines.
Staff is more durable, more resilient to future options and easier to store and transport
The shots work by exposing a person to dead viral proteins, generating antibodies when the immune system destroys him.
The companies have provided phase 3 data from the FDA test and say they plan to release the full results of the test to the public by the end of the year.
During the study, the vaccine was found to be 57.9% effective against symptomatic Covid infection. This is standard for available vaccines during the current Omicron-powered jump.
Where the vaccine really impresses is its ability to prevent the worst possible results from the virus.
Participants who received two doses of the vaccine were 75 percent less likely to suffer from severe Covid infection than their peers. None of the study members who received the stroke needed to be hospitalized or died as a result of a Covid infection.
Enhancement injection has also been shown to be effective when combined with popular mRNA vaccines such as Pfizer-BioNTech and Moderna jabs.
Sanofi and GSK report that receiving their booster after taking a two-dose regimen of jab mRNA can increase antibody levels 18 to 30-fold.
“We are very pleased with these data, which confirm our strong science and the benefits of our vaccine against COVID-19,” said Thomas Triumph, Sanofi’s executive vice president, in a statement.
“There is no other global Phase 3 efficacy study during this period with so many variants of concern, including Omicron, and these efficacy data are similar to the latest clinical data from authorized vaccines.”
Human mistake at the beginning of the vaccine trial, it postponed the companies by several months because the scientists conducting the trial misdiagnosed the wrong doses.
As a result, the whole process had to be restarted, which allowed the two pharmaceutical giants to be overtaken by Pfizer, Moderna, AstraZeneca and Johnson & Johnson.
Coincidentally, Novavax, which is also launching a protein-based vaccine that will compete directly with this one, has also faced many setbacks over the past year and until recently was unable to provide data for FDA approval.
However, health experts are excited about the prospect of a protein-based vaccine.
While mRNA jabs are easier to develop and cheaper to produce, they also have some drawbacks.
The virus can mutate more easily to evade the protection provided by vaccines – such as the Omicron variant – and vaccines must also be stored at extremely low temperatures, making vaccine delivery worldwide expensive and resource-intensive. .
Protein-based injections are thought to be more resistant to mutations and can be stored under standard cooling.
Efficacy is also expected to last longer than these injections, making the need for frequent boosters less likely.
Americans are also more aware of these photos, which could help quell the remaining population fluctuations about the vaccine.
“Many people are reluctant to be immunized. calls them anti-waxers, but I think a lot of those 20 percent [of unvaccinated Americans] are people who have completely immunized themselves and their children against [other viral diseases]. They’re just a little nervous about the mRNA vaccine, “Dr. Cody Meissner, chief FDA adviser and head of pediatrics at Tufts Children’s Hospital, told DailyMail.com.
“They may be more likely to be immunized with a more standard protein vaccine.”